This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mesothelioma Experts To Meet For 3rd International Symposium On Lung-Sparing Therapies For Malignant Pleural Mesothelioma May 18th

LOS ANGELES, March 18, 2013 /PRNewswire/ -- Mesothelioma experts will gather on Saturday, May 18 th 2013 for the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma at the Sheraton Delfina in Santa Monica, CA.  Dr. Robert B. Cameron, M.D., Director of the UCLA Mesothelioma Comprehensive Research Program, Chief of Thoracic Surgery at the West Los Angeles VA Medical Center and Scientific Advisor at Pacific Meso Center (, will again lead this year's symposium. Dr. Cameron has been a leading proponent of lung-sparing pleurectomy/decortication (P/D) surgical procedures for malignant pleural mesothelioma for nearly 20 years.

This year's meeting will include distinguished faculty and experts from prestigious universities such as UCLA, University of Pennsylvania, University of Pittsburgh, National Institutes of Health and Centro di Riferimento Oncologico CRO-Aviano in Italy.  While the seminar is primarily designed for physicians and offers continuing medical education (CME) credit, it's also open to physicians in training, nurses, mesothelioma victims, their families, students, and other interested parties.

At the 1st and 2nd annual International Symposia, specialists concluded that if surgical treatment was to be performed at all, the preferred treatment is the pleurectomy decortication (P/D) over the more radical extra-pleural pneumonectomy (EPP) surgery. P/D is an operation for mesothelioma that removes the involved pleura and frees the underlying lung so that it can expand and fill the pleural cavity, whereas EPP surgery involves the removal of the lung along with its coverings and the associated coverings of the heart, diaphragm and pericardium.

"Once again, this symposium highlights the best research and thinking by bringing the preeminent scientific and medical minds from around the world that are advancing the treatment of mesothelioma," said Dr. Cameron. "Research and practice over the past several years have continued to evolve working to improve cancer outcomes without unnecessarily sacrificing the affected lung. Clearly, it is best for the patient to treat mesothelioma as a chronic illness while preserving the function of both lungs," he added.

The Worthington Caron Law Firm ( is once again sponsoring the symposium for $50,000 as a Platinum sponsor. Gold sponsors at $15,000 are Napoli Bern ( and Simons Greenstone Panatier and Bartlett ( "The generosity of our sponsors enables us to continue to provide the most up-to-date information on treatment and therapies to the medical community. The information allows mesothelioma sufferers and their family members to make sound decisions as to their best treatment options," said Clare Cameron, Executive Director of PMC. 

Early Bird tickets can be purchased before May 3 rd online at

For more information, please contact UCLA at 310-794-2620 or call Clare Cameron at the Pacific Meso Center at Pacific Heart, Lung, Blood Institute at 310-478-4678.  

Contact: Clare Cameron310-478-4678

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE The Pacific Meso Center

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $117.52 7.90%
GOOG $691.20 -2.10%
TSLA $247.54 -1.60%
YHOO $36.58 -1.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs